Q-omics provides the consensus-scored ISCA1P6 profile across patient tissues and cancer cell-line models. ISCA1P6 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ISCA1P6 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, ISCA1P6 RNA expression shows 8,118 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and KIRC as cancer lineages where ISCA1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ISCA1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ISCA1P6 survival associations across molecular data types. ISCA1P6 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ISCA1P6 RNA expression–survival associations across cancer types. High ISCA1P6 expression shows unfavorable associations in HNSC, DLBC, ACC and MESO, but favorable associations in LUAD and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ISCA1P6 RNA expression.
This table summarizes ISCA1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ISCA1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ISCA1P6 shows lower tumor expression in KIRC, KICH, STAD, KIRP, BRCA and THCA. The KIRC box plot shows higher ISCA1P6 RNA expression in normal versus tumor tissue (log2 FC = −0.169, t-test p < 0.001).
This table shows molecular features associated with ISCA1P6 in patient tissues and cancer cell lines. In patient samples, ISCA1P6 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
